Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time on the same day.
Participants can access the conference call via webcast on Regeneron's website or by telephone after registering in advance. A replay and transcript of the call will be archived on the company's website for at least 30 days.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato che riporterà i risultati finanziari e operativi del terzo trimestre 2024 il giovedì 31 ottobre 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda organizzerà una conference call e un webcast simultaneo alle 8:30 AM ora orientale lo stesso giorno.
I partecipanti possono accedere alla conference call tramite webcast sul sito di Regeneron o telefonicamente dopo aver effettuato una registrazione anticipata. Una registrazione e un verbale della chiamata saranno archiviati sul sito dell'azienda per almeno 30 giorni.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado que informará sobre sus resultados financieros y operativos del tercer trimestre de 2024 el jueves 31 de octubre de 2024, antes de la apertura de los mercados financieros de EE. UU. La compañía llevará a cabo una conferencia telefónica y una transmisión web simultánea a las 8:30 AM, hora del Este el mismo día.
Los participantes pueden acceder a la conferencia telefónica a través de la transmisión web en el sitio web de Regeneron o por teléfono después de registrarse previamente. Una grabación y un resumen de la llamada se archivarán en el sitio de la empresa por al menos 30 días.
Regeneron Pharmaceuticals (NASDAQ: REGN)는 2024년 3분기 재무 및 운영 결과를 발표할 것이라고 발표했습니다, 2024년 10월 31일 목요일, 미국 금융 시장이 열리기 전에. 이 회사는 같은 날 동부 표준시 오전 8시 30분에 컨퍼런스 콜과 동시 웹캐스트를 주최할 예정입니다.
참가자는 사전 등록 후 Regeneron 웹사이트를 통해 웹캐스트로 컨퍼런스 콜에 접근할 수 있습니다. 통화의 리플레이와 전사는 회사 웹사이트에 최소 30일 동안 보관될 것입니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé qu'il publiera ses résultats financiers et opérationnels du troisième trimestre 2024 le jeudi 31 octobre 2024, avant l'ouverture des marchés financiers américains. L'entreprise tiendra une conférence téléphonique et un webinaire simultané à 8h30, heure de l'Est le même jour.
Les participants peuvent accéder à la conférence téléphonique via le webinaire sur le site de Regeneron ou par téléphone après s'être inscrits à l'avance. Un enregistrement et un compte rendu de l'appel seront archivés sur le site de l'entreprise pendant au moins 30 jours.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat bekannt gegeben, dass es die finanziellen und betrieblichen Ergebnisse für das dritte Quartal 2024 berichten wird am Donnerstag, den 31. Oktober 2024, bevor die US-Finanzmärkte öffnen. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen gleichzeitigen Webcast veranstalten.
Teilnehmer können über den Webcast auf der Regeneron-Website oder telefonisch nach vorheriger Registrierung auf die Telefonkonferenz zugreifen. Eine Aufzeichnung und ein Transkript des Gesprächs werden mindestens 30 Tage lang auf der Unternehmenswebsite archiviert.
- None.
- None.
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
FAQ
When will Regeneron (REGN) report its Q3 2024 financial results?
What time is Regeneron's (REGN) Q3 2024 earnings call scheduled for?
How can investors access Regeneron's (REGN) Q3 2024 earnings call?
Where can I find the replay of Regeneron's (REGN) Q3 2024 earnings call?
